US › Healthcare

Cellectar Biosciences Inc (CLRB)

US · Healthcare · Biotechnology

$2.56-3.76%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.7M
Profit YoY
+14.4%
EPS
$-1.33
EPS estimate
$-1.88

EPS came in at -1.33 against a street estimate of -1.88 — a beat of 29.3%.

Key statistics

Market cap
$21.3M
Forward P/E
0.0
P/B
7.28
Book value
$0.66
EPS (TTM)
$-5.38
52-week high
$6.52
52-week low
$2.20
50-day MA
$2.65
200-day MA
$3.08
Beta
0.56

Analyst view

Analysts rate Cellectar Biosciences Inc a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $11.50.

Shareholding

Insiders
2.07%
Institutions
16.66%

Largest institutional holders

FundStake
Bleichroeder LP1.25%
Vanguard Group Inc1.12%
Vanguard Capital Management, LLC1.02%
Geode Capital Management, LLC0.66%
Sequoia Financial Advisors LLC0.27%
Vanguard Fiduciary Trust Co0.21%
Warberg Asset Management LLC0.17%
Riverview Capital Advisers LLC0.13%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cellectar Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.